GBIO News
Archived Headlines
- Rare disease biotech Generation Bio sets terms for $126 million IPO 06/08/20
- US IPO Week Ahead: AZEK and Vroom take the lead in another 8 IPO week 06/05/20
- Rare disease biotech Generation Bio files for a $125 million IPO 05/26/20
- US IPO Weekly Recap: The IPO market picks up before Memorial Day 05/22/20
US IPO Weekly Recap: Vroom soars in another 8 IPO week
Eight IPOs and one SPAC entered the public markets this past week led by Vroom (VRM), which popped 118% in ...read more
Rare disease biotech Generation Bio prices further upsized IPO at revised $19 high end
Generation Bio, a preclinical biotech developing gene therapies for rare diseases, raised $200 million by offering 10.5 million shares at $19, the high end of the revised range of $18 to $19. The company offered 0.5 million more shares than anticipated after...read more
Rare disease biotech Generation Bio increases proposed IPO deal size by 47%
Generation Bio, a preclinical biotech developing gene therapies for rare diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Cambridge, MA-based company now plans to raise $185 million by offering 10 million shares at a price range...read more
No trial, no problem: Biggest week for preclinical biotech IPOs ever
Three large preclinical biotech IPOs are slated to begin trading on Friday, the most ever in a single week. Vaxcyte (PCVX) is developing next-generation pneumonia vaccines, a $7 billion market, and expects to begin clinical trials for its...read more